Endophthalmitis Following Intravitreal Injections Performed in the Office Versus Operating Room Setting
- 6 Downloads
Purpose of Review
To review the safety of performing intravitreal injections in the office compared with the operating room setting.
Few studies directly compare outcomes, including endophthalmitis rate, following intravitreal injections performed in the office versus operating room setting. Instead, the literature on post-injection endophthalmitis consists mostly of retrospective series separately assessing outcomes of injections performed in either the office or in the operating room. These studies consistently show that the rates of endophthalmitis are low in each setting. Of the studies reviewed, 1,220,479 unique intravitreal injections were performed in the office and 285,653 were performed in the operating room. The rate of endophthalmitis was low and similar for each (0.027%).
The current data suggests that it is safe to perform intravitreal injections in either the office or the operating room.
KeywordsEndophthalmitis Intravitreal injection Anti-vascular endothelial growth factor Injection setting Injection safety Injection complications
Compliance with Ethical Standards
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Conflict of Interest
Jason Hsu reports grants from Roche/Genentech, grants from Ophthotech and grants from Santen, outside the submitted work. Joshua H. Uhr declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.•• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–61. https://doi.org/10.1097/IAE.0b013e31820a67e4. This study by McCannel et. al. is particularly important as it is the first to report the spectrum of causative organisms responsible for EO following IVI compared with intraocular surgery. By showing that Streptococcus isolates are three times more likely after IVI, this study demonstrated the importance of oral flora for post-IVI EO, and in doing so changed our understanding of the mechanisms of post-IVI EO. Google Scholar
- 11.The Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122(6):830–46.Google Scholar
- 14.• Freiberg FJ, Brynskov T, Munk MR, Sørensen TL, Wolf S, Wirth MA, et al. Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: a retrospective multicenter study. Retina. 2017;37(12):2341–6. https://doi.org/10.1097/IAE.0000000000001488. The study by Friedberg et. al. is important as it is, as far as we can tell, the largest series to demonstrate the safety of performing IVIs in the operating room (EO rate of 0.007% following 134,701 IVIs). Google Scholar
- 16.Veringa E, van Belkum A, Schellekens H. Iatrogenic meningitis by Streptococcus salivarius following lumbar puncture. J Hosp Infect. 1995;29(4):316–8.Google Scholar
- 17.Trautmann M, Lepper PM, Schmitz FJ. Three cases of bacterial meningitis after spinal and epidural anesthesia. Eur J Clin Microbiol Infect Dis. 2002;21(1):43–5.Google Scholar
- 18.Gordon DF, Jong BB. Indigenous flora from human saliva. Appl Microbiol. 1968;16(2):428–9.Google Scholar
- 22.Buck DA, Dawkins R, Kawasaki R, Sandhu SS, Allen PJ. Survey of Victorian ophthalmologists who use ranibizumab to treat age-related macular degeneration: to identify current practice and modifiable risk factors relevant to post-injection endophthalmitis. Clin Exp Ophthalmol. 2015;43(3):277–9. https://doi.org/10.1111/ceo.12405.Google Scholar
- 31.Hansen D, Krabs C, Benner D, Brauksiepe A, Popp W. Laminar air flow provides high air quality in the operating field even during real operating conditions, but personal protection seems to be necessary in operations with tissue combustion. Int J Hyg Environ Health. 2005;208(6):455–60. https://doi.org/10.1016/j.ijheh.2005.08.008.Google Scholar
- 33.Haider MA, Imtiaz U, Javed F, Haider Z. Incidence of acute endophthalmitis after office based intravitreal bevacizumab injection. JPMA J Pak Med Assoc. 2017;67(12):1917–9.Google Scholar
- 35.Lapid-Gortzak R, Traversari R, van der Linden JW, Lesnik Oberstein SY, Lapid O, Schlingemann RO. Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intra-vitreal injection. Int Ophthalmol. 2017;37(1):131–7. https://doi.org/10.1007/s10792-016-0236-1.Google Scholar
- 39.Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol. 2013;251(8):1885–90. https://doi.org/10.1007/s00417-013-2274-y.Google Scholar
- 49.• Rayess N, Rahimy E, Storey P, Shah CP, Wolfe JD, Chen E, et al. Postinjection Endophthalmitis rates and characteristics following intravitreal bevacizumab, Ranibizumab, and Aflibercept. Am J Ophthalmol. 2016;165:88–93. https://doi.org/10.1016/j.ajo.2016.02.028. The study by Rayess et. al. is important as it is the largest to date to demonstrate the safety of performing injections in the office setting (EO rate of 0.036% following 503,890 IVIs). Google Scholar
- 51.Yannuzzi NA, Gregori NZ, Rosenfeld PJ, Relhan N, Patel NA, Si N, et al. Endophthalmitis associated with intravitreal injections of anti-VEGF agents at a tertiary referral center: in-house and referred cases. Ophthalmic Surg Lasers Imaging Retina. 2018;49(5):313–9. https://doi.org/10.3928/23258160-20180501-04.Google Scholar
- 59.Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028–34. https://doi.org/10.1016/j.ophtha.2011.02.034.Google Scholar
- 60.Rayess N, Obeid A, Storey PP, Juliano J, Rahimy E, Moshfeghi AA, et al. Long-term visual outcomes and clinical features after anti-vascular endothelial growth factor injection-related endophthalmitis. Retina. 2018. https://doi.org/10.1097/IAE.0000000000002300.
- 65.Mithal K, Mathai A, Pathengay A, Jalali S, Relhan N, Motukupally SR, et al. Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome. Br J Ophthalmol. 2013;97(12):1609–12. https://doi.org/10.1136/bjophthalmol-2013-303222.Google Scholar
- 70.Reibaldi M, Pulvirenti A, Avitabile T, Bonfiglio V, Russo A, Mariotti C, et al. Pooled estimates of incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents with and without topical antibiotic prophylaxis. Retina. 2018;38(1):1–11. https://doi.org/10.1097/IAE.0000000000001583.Google Scholar